SAN DIEGO - Poseida Therapeutics, Inc. (NASDAQ: PSTX), a biopharmaceutical company focused on developing cell and gene therapies for cancer and rare diseases, today announced the appointment of Dr. Syed Rizvi as its new Chief Medical Officer, effective April 1, 2024.
Dr. Rizvi, with over two decades of experience in drug development, will be joining the company's leadership team during a critical phase of its clinical CAR-T portfolio development.
Dr. Rizvi's career spans leadership roles in multiple organizations, where he has been instrumental in the clinical strategy, execution, and commercialization of cancer treatments, including three approved autologous CAR-T cell therapies.
His previous tenure includes serving as Chief Medical Officer at Caribou Biosciences and Chimeric Therapeutics, as well as significant positions at Legend Biotech and Celgene (NASDAQ:CELG), where he contributed to the development of approved therapies such as CARVYKTI® for myeloma and BREYANZI® for lymphoma.
Kristin Yarema, Ph.D., President and CEO of Poseida, expressed confidence in Dr. Rizvi's ability to guide the company's development and commercialization efforts. Dr. Rizvi himself highlighted Poseida's science, manufacturing capabilities, and focus on execution as key factors in his decision to join the company.
Poseida Therapeutics is advancing a pipeline that includes allogeneic CAR-T cell therapy candidates and in vivo gene therapy programs, aiming to address unmet medical needs in both solid and liquid tumors. The company is known for its proprietary genetic editing platforms and in-house cell therapy manufacturing.
The information in this article is based on a press release statement from Poseida Therapeutics, Inc. The forward-looking statements included in the press release reflect the company's expectations as of the date of the statement and are subject to risks and uncertainties that could cause actual results to differ materially.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.